Neurocrine maintained by Merrill at neutral

Neurocrine Biosciences Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating on news that the FDA pushed back the PDUFA dates for Indiplon IR and MR to a combined date of May 15. This short-term delay could result in a longer-term benefit. The FDA's review could offer a competitive advantage in the label and a combined label for IR and MR formulations would facilitate prescription of the drug, Merrill said. Shares of the San Diego biopharmaceutical company were down $1.53, or 2.37%, at $62.96 on volume of 1,490,400 shares versus the three-month running average of 580,175 shares. (Nasdaq: NBIX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.